ArticleJugan geon-gang gwa jilbyeong2024
[Introduction to the Second Malaria Re-elimination Action Plan (2024-2028) toward Malaria Eliminatiion by 2030].
Article in Jugan geon-gang gwa jilbyeong, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Molecular Surveillance ofPathogens (Basel, Switzerland) · 2026Article
- Subnational Elimination Certification System for Malaria Elimination in the Republic of Korea.Public health weekly report · 2026Article
- Commemoration of the Special Issue on Zoonotic and Vector-borne Diseases in "Public health weekly report · 2026Article
- Individual Malaria Case and Case Cluster Status in the Capital Region of the Republic of Korea, 2024.Jugan geon-gang gwa jilbyeong · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In 2019, the Republic of Korea (ROK) developed a national malaria re-elimination action plan as a priority country, designated by the World Health Organization for malaria elimination certification. In the first phase of the National Malaria Re-elimination Action Plan, efforts were made to increase early patient diagnosis and treatment rates. In 2019, the initiative included the introduction of rapid diagnostic kits under insurance coverage and the publication of the "Malaria Treatment Guidelines." Additionally, the introduction of insurance coverage for glucose-6-phosphate dehydrogenase testing in 2020 and the promotion of cluster case monitoring have also been pursued. Domestic malaria cases peaked at 4,142 in 2000, but efforts aligned with the 2019 Action Plan resulted in a decrease to 356 and 274 cases in 2020 and 2021, respectively. However, cases subsequently increased to 382 and 673 by 2022 and 2023, respectively. Consequently, the second phase of the National Malaria Re-elimination Action Plan reflects the achievements and limitations of the first phase, proposing four implementation strategies, and ten key tasks for further advancement.The second phase of ROK's Malaria Re-elimination Action Plan aims to accelerate domestic malaria elimination by 2030 by focusing on disrupting the transmission chain between patients and vectors. These efforts include implementing active surveillance, enhancing patient management, and improving vector control through scientific measures. Collaboration between government ministries, local authorities, and private medical institutions should be reinforced. The plan aims for zero malaria cases by 2028 and seeks to establish a national malaria elimination certification system.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.